Mirum Pharmaceuticals, Inc. , a biopharmaceutical company focused on rare liver disorders, announced that it will showcase multiple presentations featuring data from its LIVMARLI (maralixibat) and Volixibat clinical programmes at the The Liver Meeting, organised by the American Association for the Study of Liver Diseases (AASLD), scheduled for November 7‑11, 2025 in Washington D.C. These presentations reinforce Mirum’s dedication to advancing scientific and clinical knowledge around innovative treatments for both adult and paediatric rare liver conditions.
Health Technology Insights: Hippocratic AI Selects Fivetran to Power Trusted Data Infrastructure for AI in Healthcare
A highlight of the event will be an oral presentation of additional analyses from the VANTAGE trial, which studies volixibat in adults with primary biliary cholangitis (PBC). This presentation (Abstract #0215) is set for 3:00‑3:15 p.m. on Monday, November 10 in the session “Novel Therapies and Monitoring in Cholestatic Liver Disease,” Room 145, Level 1 of the Convention Center, and will be led by Dr Kris Kowdley of the Liver Institute Northwest, Seattle, Washington.
Health Technology Insights: Wolters Kluwer Launches Ovid Synthesis Expert AI
In addition, a series of poster presentations during the same timeframe will include: Abstract #4411 reporting real‑world use of maralixibat in PSC and its effect on cholestatic pruritus, presented by Dr Adrielly Martins (University of Miami, Florida); Abstract #4412 on the clinical utility of comprehensive genetic testing in adult cholestasis (Dr Tiziano Pramparo, Mirum, Foster City, California); Abstract #4415 exploring IL‑31 and serum bile acid regulation in PBC patients treated with ileal bile acid transporter inhibitors such as volixibat (Dr Alan Bonder, Beth Israel Deaconess Medical Center, Boston); and Abstract #4511, which reviews physician‑reported pruritus in PSC from several countries (Dr Marlyn Mayo, UT Southwestern Medical Center, Dallas, Texas). An additional poster (Abstract #4532) will show the impact of maralixibat on caregiver burden in Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) over a six‑month follow‑up (Dr Natasha Dilwali, Columbia University Irving Medical Center, New York).
Mirum will also host an educational fireside discussion titled “PFIC Diagnosis and Treatment” on Sunday, November 9 from 1:30‑2:00 p.m. in the Exhibit Hall TLM Theater, featuring Dr Robert Gish of Loma Linda University. The discussion will focus on recognising and diagnosing progressive familial intrahepatic cholestasis, the role of genetic testing, and treatment management—highlighting clinical data for LIVMARLI in PFIC.
Dr Chris Peetz, Chief Executive Officer of Mirum, said: “Our presence at this year’s Liver Meeting underscores our ongoing mission to bring forward‑thinking therapies to rare liver disease patients. The breadth of data we will share—from real‑world evidence to genetic insights and adult cholestatic disease—demonstrates how far we’ve come and how far we intend to go in improving outcomes for both children and adults.” The full abstracts are available on the AASLD website and, following the meeting, more detailed analyses will be posted in the Publications & Presentations section of Mirum’s website.
This announcement further emphasises Mirum’s commitment to building a strong clinical and scientific foundation for treating rare liver disorders and supporting patients and caregivers throughout the treatment journey.
Health Technology Insights: Cardiosense Shows AI Heart Failure Data at Transcatheter Cardiovascular Therapeutics 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
